Construction of the miRNA database associate with chemotherapeutic sensitivity in lung cancer.

吉非替尼已用于治疗非小细胞肺癌。EGFR基因突变与吉非替尼的临床应答相关。然而，尽管存在突变的EGFR基因，但一些患者对吉非替尼耐药。这种耐药性是NSCLC患者的主要问题。敏感的生物标志物是化疗药物有效治疗所必需的。近年来，循环肿瘤细胞和microRNA（microRNA，miRNA）作为肿瘤诊断的生物标志物备受关注，本研究利用miRNA阵列和实时荧光定量PCR技术，发现肺癌吉非替尼耐药细胞中部分miRNA表达显著上调。利用miRNA特异性抑制剂，我们确定ErbB家族分子是这些miRNA的靶基因。

Gefitinib has been used for treatment of non-small cell lung cancer. The EGFR gene mutation correlates with clinical response to Gefitinib. However, some patients are resistant to Gefitinib despite the existence of mutated EGFR gene. This resistance is a major problem in patients with NSCLC. Sensitive biomarker is required for effective therapy with chemotherapeutic drugs. Recently, circulating tumor cell and microRNA(miRNA) are focused on as biomarkers for cancer diagnosis.In this study, we utilized miRNA array and real-time PCR to show that some miRNAs are significantly up-regulated in Gefitinib resistant lung cancer cell lines. Using the miRNA specific inhibitors, we identified ErbB family molecules are as a target gene of these miRNAs.